- HK$127.54m
- HK$485.93m
- HK$336.11m
Brief: Purapharm Corp To Issue Consideration Shares As Licence Fee
Brief: Purapharm Says Kam Biu Tsoi, Alvin Appointed As Executive Director
Brief: Purapharm Corp Announces Lapse Of Disposal Agreement
Brief: PuraPharm Corp To Dispose Of Accounts Receivables At HK$15 Mln
Brief: PuraPharm Corp Sees Net Loss Of Not More Than HK$36 Million For FY24
Brief: Purapharm Corp Sees HY Unaudited Consol Net Loss Of Not More Than HK$20 Mln
Brief: Purapharm Corp Announces Termination Of Placing Of New Shares
Brief: Purapharm Corp Announces Placing Of New Shares Under General Mandate
Brief: Purapharm Corp Says Norimoto Hisayoshi Ceased To Be Executive Director
Brief: Purapharm Corp Posts Loss For Year Attributable Of HK$120.2 Million
Brief: Purapharm Corp Sees Net Loss Of Not More Than Hk$42 Mln For Six Months
Brief: Purapharm Posts FY Loss Attributable HK$121.9 Mln
Brief: Purapharm Corp Says Lau Ka Kuen Has Resigned As CFO
Brief: PuraPharm Says Cheong Shin Keong Re-Designated As Non-Exec Director
Brief: PuraPharm Corp Posts FY Profit Attributable Of HK$31.7 Million
Brief: PuraPharm FY Profit Attributable HK$31.7 Mln
Brief: Purapharm Says Norimoto Hisayoshi Appointed As An Executive Director
Brief: Purapharm Corp Says Unit To Sell Assets To Bagi Research For HK$12.5 Mln
Brief: Purapharm Corp Says Unit To Purchase Intellectual Properties Related To Traditional Chinese Medicine Advisor 3.0